Pharmafile Logo
Pharmafocus logo
Advanced Search

zydelig

Showing 7 posts of 7 posts found.

zydelig_gilead

Gilead cancer boss departs after safety concerns halt Zydelig trials

March 18, 2016
Medical Communications, Research and Development Gilead Sciences, zydelig

In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …

News
gilead-sciences

EMA starts review of Gilead Sciences’ Zydelig following safety concerns

March 14, 2016
Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig

Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …

News
gilead-sciences

NICE approves first in new class of leukaemia drugs

September 24, 2015
Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig

NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …

News
Zydelig image

NICE wants more answers from Gilead on Zydelig

June 18, 2015
Sales and Marketing Gilead, MabThera, NICE, Roche, UK, brett wells, zydelig

The National Institute for Health and Care Excellence has not recommended Gilead’s leukaemia drug Zydelig in draft guidance.  But the …

News
Zydelig image

Gilead’s blood cancer pill approved in Europe

September 22, 2014
Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig

Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …

News
EMA HQ

EMA approvals for rival blood cancer drugs

July 27, 2014
Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig

Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …

News
Gilead image

FDA approves Gilead’s blood cancer drug

July 24, 2014
Research and Development, Sales and Marketing Cancer, FDA, Gilead, blood, follicular lymphoma and small lymphocytic lymphoma, lymphocytic leukaemia, sovaldi, zydelig

The Food and Drug Administration has approved Gilead Sciences new treatment Zydelig (idelalisib) to treat three types of blood cancer.  …

News
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026